Oral Budesonide vs. Oral Mesalazine in Active Crohn's Disease (CD) - No Study Results Posted - ClinicalTrials.gov

Skip to Main Content

ClinicalTrials.gov

Home Search Study Topics Glossary


	Full Text View


	Tabular View


	No Study Results Posted


	Related Studies

Oral Budesonide vs. Oral Mesalazine in Active Crohn's Disease (CD)

This study has been completed.

Study NCT00300118 Information provided by Dr. Falk Pharma GmbH

First Received: March 7, 2006 Last Updated: February 2, 2011 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Study Completion Date:	May 2008
Primary Completion Date:	May 2008 (Final data collection date for primary outcome measure)

Publications:

Tromm A, Bunganic I, Tomsová E, Tulassay Z, Luká M, Kykal J, Bátovský M, Fixa B, Gabalec L, Safadi R, Kramm HJ, Altorjay I, Löhr H, Koutroubakis I, Bar-Meir S, Timac D, Glasmacher C, Dilger K, Mohrbacher R, Greinwald R; International Budenofalk® Study Group. Budesonide (9 mg) is at Least as Effective as Mesalamine (4.5 g) in Patients with Mildly to Moderately Active Crohn's disease. Gastroenterology. 2010 Nov 8; [Epub ahead of print]

Back to top of Main Content